Renesmee C. Kuo

Renesmee C. Kuo

Auto-generated profile, based on publicly available information

Renesmee C. Kuo

DEPARTMENT OF RADIOLOGY, Stanford University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Molecular Imaging
Verified
Journal Article
Open access
PDF file
PCPrashant Chandrasekharan
Prashant Chandrasekharan
RKRenesmee Kuo
Renesmee Kuo
KFK. L. Barry Fung
K. L. Barry Fung
CSChinmoy Saayujya
Chinmoy Saayujya
JBJacob Bryan
Jacob Bryan
SCSteven Conolly
Steven Conolly
Magnetic particle imaging (MPI) is a new tracer-based imaging modality that is useful in diagnosing various pathophysiology related to the vascular system and for sensitive tracking of cytotherapies. MPI uses nonradioactive and easily assimilated nanometer-sized iron oxide particles as tracers. MPI images the nonlinear Langevin behavior of the iron oxide particles and has allowed for the sensitive detection of iron oxide-labeled therapeutic cells in the body. This review will provide an overview of MPI technology, the tracer, and its use in vascular imaging and cytotherapies using molecular targets.

21 May 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MKMausam Kalita
Mausam Kalita
RKRenesmee C. Kuo
Renesmee C. Kuo
VSValentina Straniero
Valentina Straniero
SRSamantha T. Reyes
Samantha T. Reyes
MPMallesh Pandrala
Mallesh Pandrala
MJMichelle L. James
Michelle L. James
Innate immunity mediated by myeloid cells defends against infection and injury, but when chronically activated, it drives tissue damage and neurodegeneration. Molecular imaging with positron emission tomography (PET) enables noninvasive, real-time monitoring of such processes in vivo. However, most current neuroinflammation PET tracers lack specificity for activated myeloid cells. G protein–coupled receptor 84 (GPR84) is a promising biomarker that is selectively upregulated on activated microglia and macrophages. Here, we report the development and validation of two fluorine-18-labeled GPR84 tracers, [ 18 F]MGX-110S and [ 18 F]MGX-111S. Both exhibit specific binding to human GPR84-expressing cells, with [ 18 F]MGX-110S demonstrating superior affinity, selectivity, and signal-to-background ratio. [ 18 F]MGX-110S enables sensitive detection of systemic- and neuro-inflammation in LPS-treated mice and outperforms PET images obtained using a radiotracer specific for translocator protein 18 kDa in 5xFAD mice—revealing pathology-correlated activation across cortical, hippocampal, and thalamic regions. Taken together, our data indicate that [ 18 F]MGX-110S is a highly sensitive and specific tool for visualizing maladaptive myeloid cell activation; its clinical translation could enable more precise detection and staging of inflammation in addition to improved therapeutic monitoring in neurodegenerative disorders and more broadly in inflammatory diseases.

30 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
RKRenesmee C. Kuo
Renesmee C. Kuo
MCMackenzie L. Carlson
Mackenzie L. Carlson
SRSamantha T. Reyes
Samantha T. Reyes
SNSydney C. Nagy
Sydney C. Nagy
MKMausam Kalita
Mausam Kalita
MJMichelle L. James
Michelle L. James
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by infiltration of activated innate immune cells into the central nervous system (CNS). Current imaging approaches for diagnosing and monitoring disease progression rely on structural lesions and cannot directly assess innate immune activity. Here, we describe a dendrimer positron emission tomography (PET) tracer, 18F-flurimedrimer (18F-FMD), for non-invasive, longitudinal tracking of activated myeloid cells. In an experimental autoimmune encephalomyelitis (EAE) murine model, 18F-FMD specifically detects myeloid activation at presymptomatic and symptomatic stages, with PET signal correlating with disease severity. Moreover, 18F-FMD sensitively captures therapeutic response to fingolimod (FTY720) and a CSF1R dendranib (H74DS3M8), both of which suppress immune cell activation and attenuate disease severity. These findings highlight the potential of 18F-FMD PET for specific, real-time monitoring of innate immune responses, and the applicability of the dendrimer in clinical settings for monitoring therapeutic efficacy, advancing the development of personalized, myeloid-targeted strategies for MS.

19 March 2023
Verified
Journal Article
Open access
ODOwen Doyle
Owen Doyle
JBJacob Bryan
Jacob Bryan
MKMelissa Kim
Melissa Kim
CSChinmoy Saayujya
Chinmoy Saayujya
SNSophie Nazarian
Sophie Nazarian
SCSteven Conolly
Steven Conolly
Magnetic Particle Imaging (MPI) is a tracer-based imaging modality with immense promise as a radiation-free alternative to nuclear medicine imaging techniques. Nuclear medicine requires “hot chemistry” wherein radioactive tracers must be synthesized on-site, requiring expensive infrastructure and labor costs. MPI’s magnetic nanoparticles, superparamagnetic iron oxide nanoparticles (SPIOs), have no significant signal decay over time which removes cost barriers associated with nuclear medicine studies such as FDG-PET. While SPIOs are the current industry standard MPI tracer, recent developments in synthesizing superferromagnetic iron oxide nanoparticles (SFMIOs) and high resolution SPIOs (HR-SPIOs), a new class of nanoparticle with almost zero coercivity, have yielded a 30-fold improvement in resolution (0.4 mT) and SNR. To better understand the long-term performance of these new nanoparticles, this investigation reports changes in SPIO (VivoTrax Plus), HR-SPIO, and SFMIO resolution, along with SFMIO coercivity, at low temperatures (−2, 2 °C) and room temperature (18–22 °C) over 12 weeks. We find that changes in HR-SPIO resolution are more sensitive to storage temperature than SFMIOs. Additionally, we observe no appreciable difference in SFMIO coercivity between the two temperatures over time. These results can inform research on optimizing tracer synthesis while lending practical information to future hospitals about the highly accessible conditions for the transit and storage of tracers.

15 August 2026 in Advanced Science
Verified
Journal Article
Open access
RKRenesmee C. Kuo
Renesmee C. Kuo
RVRohit Verma
Rohit Verma
SNSydney C. Nagy
Sydney C. Nagy
MKMausam Kalita
Mausam Kalita
SASamuel Aubert
Samuel Aubert
MJMichelle L. James
Michelle L. James
Immune checkpoint inhibitors (ICIs) have transformed outcomes for melanoma brain metastases (MBM), yet early response assessment remains challenging because currently available tools such as magnetic resonance imaging (MRI) lack molecular specificity and are confounded by pseudoprogression. Antibody‐based positron emission tomography (immunoPET) is a highly sensitive and specific molecular imaging technique that enables noninvasive, whole‐body visualization of immune dynamics in vivo. The inducible T cell costimulatory receptor (ICOS) is a promising biomarker of therapy‐induced T cell activation. Here, a previously validated tracer, [ 89 Zr]DFO‐ICOS mAb, is used to track activated T cells in a murine MBM model treated with combined anti‐PD‐1/anti‐CTLA‐4 therapy, and immunoPET signal is shown to correspond with therapeutic response and intratumoral T cell activation. To establish clinical relevance of ICOS‐immunoPET, single‐cell RNA sequencing data from 6 human MBM specimens are reanalyzed, revealing significantly higher ICOS expression accompanied by coordinated activation signatures in ICI‐treated tumors. These findings support ICOS‐immunoPET as a promising strategy for earlier, noninvasive, functionally informative assessment of immunotherapy response, with potential to improve patient stratification in brain metastases.

6 February 2025 in Research Square
Verified
Preprint
Open access
PDF file
MJMichelle James
Michelle James
RKRenesmee Kuo
Renesmee Kuo
MCMackenzie Carlson
Mackenzie Carlson
SRSamantha Reyes
Samantha Reyes
SNSydney Nagy
Sydney Nagy
JCJeffrey Cleland
Jeffrey Cleland
Multiple sclerosis (MS) is a chronic neurodegenerative disease driven by immune cell infiltration into the central nervous system (CNS). Despite the critical role of immune cells in MS initiation and progression, current standard of care imaging techniques rely on structural lesion assessments, often resulting in misdiagnoses and inaccurate disease staging. Here we describe a novel dendrimer positron emission tomography (PET) tracer, 18 F-flurimedrimer ( 18 F-FMD), for non-invasive detection and tracking of activated myeloid cells–key immune players in MS. Using an experimental autoimmune encephalomyelitis (EAE) murine model of MS, we demonstrate the ability of 18 F-FMD to specifically detect these cells at both presymptomatic and symptomatic stages, with signal intensity correlating with disease severity. We illustrate that 18 F-FMD can also accurately monitor the immunomodulatory effects of Food and Drug Administration (FDA)-approved disease-modifying MS drug fingolimod (FTY720) and a novel CSF1R dendranib (H74DS3M8), both of which reduced immune cell activation and halted disease progression. These findings highlight the potential of 18 F-FMD PET for early MS diagnosis and as a generalizable approach for real-time monitoring of therapeutic responses across various mechanisms. Since we have translated 18 F-FMD for clinical imaging, it has the potential to revolutionize patient stratification in clinical trials and optimize treatments, making precision medicine a reality for MS patients.